BELLUS Health Inc
TSX:BLU
Intrinsic Value
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of BLU.
BELLUS Health Inc's market capitalization is 2.5B CAD.
BLU stock price is 19.48 CAD.
BLU.
BLU. Open DCF Valuation
BLU. Open Relative Valuation
BLU's ROE (Return on Equity) has increased in the last 3 years from -29% to -27%, and is approaching profitability.
BLU's Revenue has dropped by 6% over the past 12 months.
BLU's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -79% to -174%, and is approaching profitability.
BLU has negative Operating Income for the last twelve months.
BLU has negative Net Income for the last twelve months.
BLU's ROE (Return on Equity) for the past 12 months is negative and is equal to -27%.
BLU's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -174%.
BLU's Revenue has been falling by 21% per year for the last 3 years.
BLU's Revenue is forecast to grow at a rate of 439% per year over the next 3 years.
BLU has negative Free Cash Flow for the last twelve months.
BLU's D/E (Debt to Equity) is very low and is equal to 0.
BLU has negative three-year average ROE (Return on Equity): -35%. The company is not efficient at transforming stockholders' equity into net income.
BLU has negative three-year average ROIC (Return on Invested Capital): -146%. The company is not efficient at using invested capital to generate operating income.
BLU's short-term assets (328m USD) exceed its short-term liabilties (10m USD).
BLU's long-term assets (380m USD) exceed its long-term liabilties (11m USD).
BLU has negative Net Debt. This means that the company has more cash and short-term investments (313m USD) than debt (834k USD).
BLU's Altman Z-Score is very high and is equal to 66.32.
BLU doesn't generate enough operating income (-90m USD) to safely cover interest payments on its debt (33k USD).
Fundamental Analysis
BELLUS Health Inc
Balance Sheet Decomposition
BELLUS Health Inc
| Current Assets | 327.7m |
| Cash & Short-Term Investments | 313m |
| Receivables | 2m |
| Other Current Assets | 12.7m |
| Non-Current Assets | 51.8m |
| PP&E | 1.2m |
| Intangibles | 50.1m |
| Other Non-Current Assets | 528k |
| Current Liabilities | 9.8m |
| Accounts Payable | 9.4m |
| Other Current Liabilities | 365k |
| Non-Current Liabilities | 834k |
| Long-Term Debt | 834k |
Earnings Waterfall
BELLUS Health Inc
|
Revenue
|
15k
USD
|
|
Operating Expenses
|
-90.3m
USD
|
|
Operating Income
|
-90.3m
USD
|
|
Other Expenses
|
3.5m
USD
|
|
Net Income
|
-86.8m
USD
|
Free Cash Flow Analysis
BELLUS Health Inc
What is Free Cash Flow?
BLU Profitability Score
Profitability Due Diligence
BELLUS Health Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
BELLUS Health Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
BLU Solvency Score
Solvency Due Diligence
BELLUS Health Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
BELLUS Health Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLU Price Targets Summary
BELLUS Health Inc
According to Wall Street analysts, the average 1-year price target for
BLU
is 20.66 CAD
.
Shareholder Return
BLU Price
BELLUS Health Inc
| Average Annual Return | 61.21% |
| Standard Deviation of Annual Returns | 108.89% |
| Max Drawdown | -82% |
| Market Capitalization | 2.5B CAD |
| Shares Outstanding | 126 799 000 |
| Percentage of Shares Shorted | 2.09% |
BLU News
Last Important Events
BELLUS Health Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
BELLUS Health Inc
Company Profile
BELLUS Health Inc
Country
Industry
Market Cap
Dividend Yield
Description
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 40 full-time employees. The company went IPO on 2000-06-22. The Company’s lead candidate, BLU-5937, is being studied in Phase II clinical trials in refractory chronic cough and chronic pruritus associated with atopic dermatitis. The company is developing BLU-5937 for the treatment of chronic cough and chronic pruritus, or chronic itch. The firm is focused on SOOTHE, which is in a Phase IIb trial of BLU-5937 in refractory chronic cough patients. The company is also focused on BLUEPRINT, which is in a Phase II trial in chronic pruritus associated with atopic dermatitis. The RELIEF trial established proof-of-concept for BLU-5937 in the treatment of RCC patients.
You don't have any saved screeners yet
